We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · December 04, 2014

Personalized Chemotherapy Based on Tumor Marker Decline in Poor Prognosis Germ-Cell Tumors

The Lancet Oncology


Additional Info

The Lancet Oncology
Personalised Chemotherapy Based on Tumour Marker Decline in Poor Prognosis Germ-Cell Tumours (GETUG 13): A Phase 3, Multicentre, Randomised Trial
Lancet Oncol 2014 Dec 01;15(13)1442-1450, K Fizazi, L Pagliaro, A Laplanche, A Fléchon, J Mardiak, L Geoffrois, P Kerbrat, C Chevreau, R Delva, F Rolland, C Theodore, G Roubaud, G Gravis, JC Eymard, JP Malhaire, C Linassier, M Habibian, AL Martin, F Journeau, M Reckova, C Logothetis, S Culine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading